Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | CDK1 | P06493 | 10/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3350947 | 0.88 | MAPK1 (0.51) | SYKIGF1RSTK17A | |
| SCHEMBL3450104 | 0.84 | CDK1 (0.47) | KDRCDK1CDK2 | |
| SCHEMBL13420484 | 0.84 | SYK (0.40) | KDRCDK1CDK2SYKAURKA | |
| SCHEMBL3450501 | 0.82 | HDAC3 (0.44) | KDRCDK1CDK2SYKAURKA | |
| SCHEMBL4584347 | 0.79 | IGF1R (0.48) | KDRCDK1CDK2SYKGSK3B | |
| SCHEMBL13420174 | 0.77 | SYK (0.54) | KDRCDK2SYKAURKAIGF1R | |
| SCHEMBL3448927 | 0.77 | CDK1 (0.44) | KDRCDK1CDK2EIF2AK2 | |
| SCHEMBL3344744 | 0.74 | SYK (0.56) | CDK1CDK2SYKGSK3BIGF1R | |
| SCHEMBL3447995 | 0.74 | IGF1R (0.47) | CDK2SYKAURKAIGF1R | |
| SCHEMBL3348225 | 0.74 | IGF1R (0.55) | CDK2SYKGSK3BIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | KDR 4837/4885CDK1 1871/4885CDK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.